Meeting
2023 ASCO Gastrointestinal Cancers Symposium
Management (mgmt) of futibatinib-associated adverse events (AEs) in patients (pts) with advanced cancers: Results of a pooled analysis.
Authors
Funda Meric-Bernstam
University of Texas MD Anderson Cancer Center, Houston, TX;
Funda Meric-Bernstam , Antoine Hollebecque , Junji Furuse , Do-Youn Oh , John A. Bridgewater , Masashi Shimura , Bailey Anderson , Nanae Hangai , Volker Wacheck , Lipika Goyal
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Track
Pancreatic Cancer,Hepatobiliary Cancer,Neuroendocrine/Carcinoid,Small Bowel Cancer
Sub Track
Therapeutics
Clinical Trial Registration Number
NCT02052778/JapicCTI-142552
Citation
J Clin Oncol 41, 2023 (suppl 4; abstr 586)
DOI
10.1200/JCO.2023.41.4_suppl.586
Abstract #
586
Poster Bd #
E18
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Capivasertib (C) and fulvestrant (F) for patients (pts) with aromatase inhibitor (AI)-resistant HR+/HER2– advanced breast cancer (ABC): Characterization and management of common adverse events (AEs) from the phase 3 CAPItello-291 trial.
First Author: Hope S. Rugo
Poster
2022 ASCO Genitourinary Cancers Symposium
Futibatinib plus pembrolizumab in patients (pts) with advanced or metastatic urothelial carcinoma (mUC): Preliminary safety results from a phase 2 study.
First Author: Vadim S Koshkin
Poster
2022 ASCO Gastrointestinal Cancers Symposium
Indirect treatment comparison of futibatinib with chemotherapy and pemigatinib in cholangiocarcinoma with FGFR2 fusions/rearrangements.
First Author: Mitesh J. Borad
Poster
2022 ASCO Gastrointestinal Cancers Symposium
Emerging treatments for advanced cholangiocarcinoma: Addressing the knowledge gap.
First Author: Elizabeth J Heller